Shots:

• The P-III LELANTOS-2 study will assess Pamrevlumab + systemic corticosteroids vs PBO + systemic corticosteroids in ~70 patients aged 6-12yrs. in a ratio (1:1) with ambulatory DMD for up to 52wks.
• The focus of the study is to assess the effect of Pamrevlumab on muscle function in patients with DMD with 1EPs as an ambulatory function assessment- measured by NSAA. Additionally- 2EPs will be assessed in the study
• Patients who complete the 52wks. study will be eligible for rollover into an OLE study with Pamrevlumab and systemic corticosteroids. Pamrevlumab is a first-in-class antibody that inhibits the activity of CTGF

 ­ Ref: Fibrogen | Image: Fibrogen